ArticleFrontiers in pediatrics2026
Case Report: BKV-specific T cells: a fast, safe and potentially effective treatment option for refractory BKV infections in pediatric patients after allogeneic stem cell transplantation.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BK virus reactivation is frequently observed in patients following allogeneic stem cell transplantation and can cause nephropathy and hemorrhagic cystitis. Current treatments are mainly supportive, and antiviral therapy with cidofovir lacks clear evidence of efficacy. Therefore, novel therapeutic strategies are needed. Since adoptive transfer of virus-specific T cells has proven effective for other viral infections, this case series with four cases of post-transplant severe BKV infections evaluated the feasibility, safety, and efficacy of BKV-specific T cells in patients with refractory BKV infection using the CliniMACS Prodigy system. Three of the four patients demonstrated a reduction in BKV viral load following adoptive T-cell transfer, with detectable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.